Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) and Alector (NASDAQ:ALEC – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.
Valuation & Earnings
This table compares Entrada Therapeutics and Alector”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Entrada Therapeutics | $25.42 million | 7.15 | -$143.75 million | ($3.84) | -1.21 |
| Alector | $21.05 million | 16.27 | -$142.93 million | $0.35 | 6.57 |
Alector has lower revenue, but higher earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Entrada Therapeutics has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Comparatively, Alector has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.
Institutional and Insider Ownership
86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by insiders. Comparatively, 8.3% of Alector shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Entrada Therapeutics and Alector’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entrada Therapeutics | -4,057.98% | -64.00% | -50.49% |
| Alector | 23.87% | 112.21% | 18.37% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Entrada Therapeutics and Alector, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entrada Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| Alector | 2 | 1 | 3 | 1 | 2.43 |
Entrada Therapeutics currently has a consensus target price of $16.75, suggesting a potential upside of 260.99%. Alector has a consensus target price of $5.10, suggesting a potential upside of 121.74%. Given Entrada Therapeutics’ higher probable upside, equities analysts clearly believe Entrada Therapeutics is more favorable than Alector.
Summary
Alector beats Entrada Therapeutics on 8 of the 13 factors compared between the two stocks.
About Entrada Therapeutics
Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.
About Alector
Alector, Inc. is a biotechnology company based in South San Francisco, California, that develops investigational therapies for neurodegenerative diseases. Its research focuses on the role of the immune system in the brain and how immune pathways may be used to address disease processes. The company’s approach draws on human genetics and immunology to identify potential therapeutic targets. Its research has included programs targeting progranulin and TREM2, proteins associated with brain health and neurodegenerative disease.
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
